If you manufacture, distribute, or supply corneal storage medium with preservatives — including antifungals — the FDA just changed the regulatory landscape for your product. On May 6, 2026, the FDA published a final order in the Federal Register classifying this device type into Class II (Special Controls). That shift carries real compliance implications, and the window to understand them is narrow.
The lesson here is not that the FDA created a new hurdle for its own sake. The lesson is that devices handling donor corneal tissue sit at the intersection of patient safety and transplant medicine, and regulators have decided that general controls alone are no longer sufficient. If your quality system hasn't been built with that premise in mind, this classification order is a prompt to revisit it.
What the FDA Actually Did
The final order, published under Docket No. FDA-2025-N-XXXX and codified through the Federal Register document 2026-08813, formally classifies the corneal storage medium with preservatives including antifungals into Class II under 21 CFR Part 886 (Ophthalmic Devices).
Prior to this order, corneal storage media occupied a regulatory gray zone — evaluated on a device-by-device basis without a defined classification home. The FDA has now determined that Class II, with specific special controls, provides a reasonable assurance of safety and effectiveness. That means a general controls-plus-special-controls framework now governs these devices, and premarket notification (510(k)) submission is the applicable pathway unless an exemption applies.
According to the Federal Register publication, the special controls identified in the order will become part of the codified classification language for this device type. That's not a guidance document you can treat as optional — it becomes regulatory text.
Why Class II, and Why Now
The FDA's rationale is worth understanding, because it shapes how you think about compliance. Corneal storage media are used to preserve donor corneal tissue between procurement and transplant. They are not implanted directly, but the cornea that sits in them absolutely is. Any contamination, degradation of efficacy, or incompatibility with the tissue doesn't show up until a patient is on the table — or worse, afterward.
The inclusion of antifungals in the device name is deliberate. Fungal contamination of donor corneal tissue has been a documented source of post-transplant infections, including endophthalmitis, which can lead to permanent vision loss. The FDA's classification decision reflects accumulated evidence that this risk profile warrants more than general controls.
In my view, this is the FDA being appropriately proactive rather than reactive. The alternative — waiting for a cluster of serious adverse events before formalizing oversight — would have been the wrong call. Class II with special controls is the agency saying, we have enough information to define what good looks like for this device type; now define it.
What Are the Special Controls?
Special controls under Class II serve as the mechanism by which the FDA identifies device-specific requirements that general controls alone can't address. For corneal storage media with preservatives including antifungals, the special controls established in this order address several areas. Based on the classification structure and the nature of this device type, manufacturers should expect requirements spanning:
| Special Control Area | What It Addresses |
|---|---|
| Performance testing | Demonstrated efficacy in preserving corneal tissue viability over the labeled storage period |
| Microbial testing | Sterility and antimicrobial efficacy of the preservative system, including antifungal activity |
| Biocompatibility | Evaluation per ISO 10993 to confirm the medium does not adversely affect corneal tissue |
| Labeling requirements | Clear identification of preservatives, storage conditions, expiration, and intended use |
| Device-specific standards | Compliance with applicable ASTM or USP standards for ophthalmic preparations |
| Shelf-life / stability testing | Data demonstrating the medium maintains its properties through the claimed shelf life |
These controls become the floor, not the ceiling. Your technical file needs to demonstrate conformance with each one.
The 510(k) Pathway: What This Means in Practice
With Class II classification confirmed, manufacturers of corneal storage medium with preservatives including antifungals will generally need to submit a 510(k) premarket notification to the FDA before marketing. The 510(k) must demonstrate substantial equivalence to a legally marketed predicate device.
A few practical points on that:
Finding a predicate matters more than it used to. Now that there is a defined classification with codified special controls, predicates within the same classification bucket carry more weight. A predicate that was cleared under Class II with the same special controls is a stronger foundation than a historical device cleared before the classification existed.
Your performance data needs to map to the special controls. I've seen 510(k)s fail not because the product was unsafe, but because the data package didn't speak the language of the special controls. Build your testing program around the specific controls enumerated in the order — not just your general sense of what good testing looks like.
Combination product questions may arise. If your corneal storage medium is packaged with or marketed alongside a container or carrying case that independently meets the device definition, assess whether you have a combination product scenario that requires additional classification review.
Effective Dates and Deadlines
The final order was published May 6, 2026. For classification orders of this type, the effective date of the codified classification is typically the date of publication or shortly thereafter — confirm the specific effective date in the Federal Register document at federalregister.gov/documents/2026/05/06/2026-08813.
Manufacturers with currently marketed products should evaluate:
-
Whether their existing product falls within the scope of this classification. The device name — "corneal storage medium with preservatives including antifungals" — is specific. If your product does not include antifungals, confirm whether a separate classification applies or whether the general corneal storage medium classification covers your device type.
-
Whether a 510(k) is already on file. If you previously received 510(k) clearance under a different classification framework, you will want to assess whether your clearance remains valid under the new codified classification, or whether a new submission is warranted to align with the special controls.
-
Whether your labeling and technical documentation need updating. Special controls often impose labeling requirements that weren't part of the original predicate comparison. Review your current labeling against the new codified requirements.
The FDA generally provides a transition period for devices already on the market — check the final order for any enforcement discretion language or transition provisions.
Quality System Implications Under ISO 13485
If you're reading this as a quality professional operating under ISO 13485:2016, the classification change has direct implications for your QMS even if you're not the legal manufacturer.
Clause 7.3 (Design and Development): Your design inputs need to be updated to reflect the special controls as regulatory requirements. If special controls establish specific performance thresholds or testing standards, those become design inputs under your design control procedure.
Clause 7.4 (Purchasing): If you source corneal storage medium from a supplier as a component of a larger system, you need to verify your supplier has addressed the new classification requirements. This is a supplier qualification trigger.
Clause 8.2.3 (Monitoring and Measurement of Processes): Your process validation and in-process monitoring should be reviewed against the special controls for performance and microbial testing. If gaps exist, address them proactively.
Clause 4.1 (General Requirements): Your regulatory affairs documentation should reflect the updated classification. If you maintain a regulatory strategy document or a global regulatory overview, update it now.
For organizations pursuing or maintaining ISO 13485 certification, auditors will be looking at whether your QMS reflects current regulatory requirements. A classification change that isn't reflected in your design inputs, risk management files, or technical documentation is the kind of gap that generates nonconformances — and avoidable ones.
You can learn more about building a QMS that keeps pace with regulatory changes in our ISO 13485 implementation guide.
Risk Management Under ISO 14971
The antifungal preservative component of this device deserves particular attention in your risk management file under ISO 14971:2019.
The known hazard associated with antifungal agents in ophthalmic preparations includes potential cytotoxicity to corneal endothelial cells. The special controls' biocompatibility requirement exists precisely because this is a recognized risk. Your ISO 14971 risk analysis should:
- Identify fungal contamination of donor tissue as a hazard
- Identify preservative-related cytotoxicity as a separate, competing hazard
- Document the risk-benefit analysis that justifies the preservative system used
- Include post-market surveillance data or literature review supporting the chosen antifungal agent and concentration
In my experience working with ophthalmic device manufacturers, the risk files for preservation media sometimes treat the medium as a passive container rather than an active component. It isn't passive — it's doing chemistry on living tissue. The risk file should reflect that.
Three Things to Do This Month
Given the May 2026 publication date, here's where I'd focus energy right now:
1. Scope determination. Pull your product's current classification status and compare it against the new 21 CFR classification code. Confirm whether your device is in scope, out of scope, or on the boundary. If you're not sure, this is the right time to engage a regulatory consultant — ambiguity here is expensive later.
2. Gap analysis against special controls. Map your existing technical documentation, testing data, and labeling against each special control enumerated in the order. Treat this as a mini-audit. The gaps you find now are cheaper to fix than the gaps an FDA reviewer finds in your 510(k) review.
3. 510(k) strategy decision. If you need to submit — or re-submit — get your strategy in place before the technical work begins. The predicate selection, the special controls matrix, and the performance data package all need to be designed together. Building them sequentially costs time you may not have.
If you want a structured framework for approaching 510(k) submissions for ophthalmic devices, our 510(k) preparation resources walk through the process step by step.
A Final Observation
Class II classifications don't always get the attention they deserve from smaller manufacturers, because Class II sounds less serious than Class III. That's a mistake. The special controls that accompany a Class II classification are enforceable regulatory requirements — not best practice recommendations. The FDA can take action against devices marketed without a required 510(k) clearance, and "we weren't aware the classification had changed" is not a defense that tends to go well.
The good news is that the FDA's decision to classify this device type into Class II rather than Class III signals that the agency believes the risk can be managed with defined controls — it doesn't believe this is an unmanageable risk profile. That's the right frame. The special controls exist to make compliance achievable and auditable. Use them.
Last updated: 2026-05-11
Source: Federal Register, Vol. 91, Document 2026-08813, published May 6, 2026. Available at federalregister.gov/documents/2026/05/06/2026-08813.
Jared Clark
Principal Consultant, Certify Consulting
Jared Clark is the founder of Certify Consulting, helping organizations achieve and maintain compliance with international standards and regulatory requirements.